Bentley Pharmaceuticals Retains Porter, Le Vay & Rose as Its Investor Relations Counsel.

EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company focused on advanced drug delivery technologies, which also manufactures and markets a growing branded and generic product line in Europe, announced today that it has retained New York-based Porter, Le Vay & Rose (PLR) as its investor relations counsel.

Bentley's business generates revenues through manufacturing and marketing of branded pharmaceuticals, generic pharmaceuticals, licensing and supply collaborations with other pharmaceutical companies and export sales to customers, primarily in Europe. It also receives royalties from Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), based upon sales of its Testim(TM) testosterone gel, and it has recently signed a collaboration agreement with Perrigo Co. (NASDAQ: PRGO) for the introduction of products into the United States. Bentley's product line currently includes: Lansoprazole and Omeprazole, gastrointestinal products used to prevent ulcers and to treat gastric hyperacidity; Simvastatin, a lipid-lowering agent used to fight high cholesterol; Enalapril, an ACE inhibitor used to lower blood pressure; Paroxetine, an anti- depressant; and Pentoxifylline, prescribed for peripheral arterial disease among its many other products. The majority of its products are generic versions of brand name pharmaceuticals. In addition, Bentley currently has over 100 product registrations in its development pipeline pending approval throughout the European Union and other countries in geographical Europe.

James R. Murphy, Bentley's chairman and CEO, said, "We have an ambitious business plan to transform our Company into a global pharmaceutical operation. In order to keep the financial markets updated on the implementation of this program, we felt the need to re-engage the services of Porter, Le Vay & Rose, a New York-based IR firm that has a successful track record with our management team, our corporate culture and our product line."

Michael J. Porter, president of PLR, said, "We are very pleased to have Bentley Pharmaceuticals back as a client, especially at a time when the Company is poised to become a recognized global operation. We have designed a communications program that will effectively inform all market participants, both buy-side and sell-side, of the developments at Bentley. We intend to expand analyst coverage, put the management team on the road to increase ties to the financial markets, and schedule regular teleconferences."

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries, Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar; and manufactures and markets active pharmaceutical ingredients through its subsidiary, Bentley API.

Copies of Bentley Pharmaceuticals' press releases and other information may be obtained through Bentley's web site at www.bentleypharm.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including without limitation, statements regarding Bentley's business plan for globalization. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to risks associated with the timing and results of clinical trials, efficacy and safety of our products, the timing and nature of regulatory approvals, expanding generic and branded drug operations, changes in third-party reimbursement and government mandates which impact pharmaceutical pricing, development and commercialization of our products, competition from other manufacturers of generic and proprietary pharmaceuticals, intellectual property litigation, our relationships with our strategic partners, the unpredictability of patent protection, technological changes, the effects of economic conditions, risks associated with international operations, and other uncertainties detailed in Bentley's most recent Annual Report on Form 10-K and its other subsequent periodic reports filed with the Securities and Exchange Commission. Bentley cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Bentley undertakes no obligation to update or revise the statements, except as may be required by law.